english.prescrire.org > Prescrire International > N°161 - June 2015

n°161

June 2015

Issue Contents
Editorial

Free  Corticosteroids: out of fashion?

p.144
Trading the known for the unknown

New Products


Rituximab (Mabthera°) and severe polyangiitis

p.145-148
An option for patients informed of the uncertainties

INN common stem: -tide

p.148

Ponatinib (Iclusig°)

p.149
Philadelphia chromosome-positive leukaemia: uncertain efficacy, proven thromboembolic risk

Free  Dabigatran (Pradaxa°): deep vein thrombosis and pulmonary embolism

p.150
Warfarin remains the standard drug

Ranibizumab (Lucentis°) in high myopia with neovascularisation

p.151
Better short-term visual acuity but serious adverse effects

Omalizumab and chronic spontaneous urticaria

p.152
Too many adverse effects and uncertainties

Febuxostat (Adenuric°): toxic epidermal necrolysis and severe hypersensitivity reactions added to the SPC

p.153
No better than allopurinol

Adverse Effects


Methylphenidate: pulmonary hypertension and heart valve disease

p.154-155
Epidemiological studies are needed

Mechanisms of action of amphetamine-like drugs

p.155

Red yeast rice: muscle and liver disorders

p.156
Natural, yet risky

Hydroxychloroquine: hypoglycaemia

p.156
Inform diabetic patients

Efavirenz: suicides

p.156
Beware of behavioural changes

Reviews


Smoking cessation during pregnancy

p.157-159
Nicotine replacement, e-cigarettes

Epicondylitis and corticosteroid injection: fewer cures at one year

p.160-161
Pros and cons of corticosteroids

Outlook


How INNs are created

p.162-165
Making drug names safer by contributing to INN selection

Free  Facts and figures

p.166-167
The finances of Association Mieux Prescrire: 2014 Prescrire annual report

Masthead


Free  Masthead

p.142

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe